Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy
© The author(s)..
Diabetic retinopathy (DR) is associated with retinal neovascularization, hard exudates, inflammation, oxidative stress and cell death, leading to vision loss. Anti-vascular endothelial growth factor (Anti-VEGF) therapy through repeated intravitreal injections is an established treatment for reducing VEGF levels in the retina for inhibiting neovascularization and leakage of hard exudates to prevent vision loss. Although anti-VEGF therapy has several clinical benefits, its monthly injection potentially causes devastating ocular complications, including trauma, intraocular hemorrhage, retinal detachment, endophthalmitis, etc. Methods: As mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) demonstrated safety in clinical studies, we have tested the efficacy of MSC-derived small EVs (MSC-sEVs) loaded anti-VEGF drug bevacizumab in a rat model of DR. Results: The study identified a clinically significant finding that sEV loaded with bevacizumab reduces the frequency of intravitreal injection required for treating diabetic retinopathy. The sustained effect is observed from the reduced levels of VEGF, exudates and leukostasis for more than two months following intravitreal injection of sEV loaded with bevacizumab, while bevacizumab alone could maintain reduced levels for about one month. Furthermore, retinal cell death was consistently lower in this period than only bevacizumab. Conclusion: This study provided significant evidence for the prolonged benefits of sEVs as a drug delivery system. Also, EV-mediated drug delivery systems could be considered for clinical application of retinal diseases as they maintain vitreous clarity in the light path due to their composition being similar to cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Theranostics - 13(2023), 7 vom: 21., Seite 2241-2255 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reddy, Shivakumar K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.05.2023 Date Revised 13.05.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.7150/thno.78426 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356568725 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356568725 | ||
| 003 | DE-627 | ||
| 005 | 20231226070736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7150/thno.78426 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356568725 | ||
| 035 | |a (NLM)37153730 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reddy, Shivakumar K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2023 | ||
| 500 | |a Date Revised 13.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The author(s). | ||
| 520 | |a Diabetic retinopathy (DR) is associated with retinal neovascularization, hard exudates, inflammation, oxidative stress and cell death, leading to vision loss. Anti-vascular endothelial growth factor (Anti-VEGF) therapy through repeated intravitreal injections is an established treatment for reducing VEGF levels in the retina for inhibiting neovascularization and leakage of hard exudates to prevent vision loss. Although anti-VEGF therapy has several clinical benefits, its monthly injection potentially causes devastating ocular complications, including trauma, intraocular hemorrhage, retinal detachment, endophthalmitis, etc. Methods: As mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) demonstrated safety in clinical studies, we have tested the efficacy of MSC-derived small EVs (MSC-sEVs) loaded anti-VEGF drug bevacizumab in a rat model of DR. Results: The study identified a clinically significant finding that sEV loaded with bevacizumab reduces the frequency of intravitreal injection required for treating diabetic retinopathy. The sustained effect is observed from the reduced levels of VEGF, exudates and leukostasis for more than two months following intravitreal injection of sEV loaded with bevacizumab, while bevacizumab alone could maintain reduced levels for about one month. Furthermore, retinal cell death was consistently lower in this period than only bevacizumab. Conclusion: This study provided significant evidence for the prolonged benefits of sEVs as a drug delivery system. Also, EV-mediated drug delivery systems could be considered for clinical application of retinal diseases as they maintain vitreous clarity in the light path due to their composition being similar to cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Diabetic retinopathy | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a intravitreal injection | |
| 650 | 4 | |a neovascularization. | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Ballal, Abhijna R |e verfasserin |4 aut | |
| 700 | 1 | |a Shailaja, S |e verfasserin |4 aut | |
| 700 | 1 | |a Seetharam, Raviraja N |e verfasserin |4 aut | |
| 700 | 1 | |a Raghu, Chandrashekar H |e verfasserin |4 aut | |
| 700 | 1 | |a Sankhe, Runali |e verfasserin |4 aut | |
| 700 | 1 | |a Pai, Kanthilatha |e verfasserin |4 aut | |
| 700 | 1 | |a Tender, Tenzin |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Aroor, Annayya |e verfasserin |4 aut | |
| 700 | 1 | |a Shetty, Ashok K |e verfasserin |4 aut | |
| 700 | 1 | |a Adiga, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Devi, Vasudha |e verfasserin |4 aut | |
| 700 | 1 | |a Muttigi, Manjunatha S |e verfasserin |4 aut | |
| 700 | 1 | |a Upadhya, Dinesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Theranostics |d 2011 |g 13(2023), 7 vom: 21., Seite 2241-2255 |w (DE-627)NLM20717458X |x 1838-7640 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:7 |g day:21 |g pages:2241-2255 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7150/thno.78426 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 7 |b 21 |h 2241-2255 | ||